UK markets closed
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • FTSE 250

    17,972.69
    -359.00 (-1.96%)
     
  • AIM

    833.59
    -13.83 (-1.63%)
     
  • GBP/EUR

    1.1189
    -0.0251 (-2.19%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.54%)
     
  • BTC-GBP

    17,615.61
    -26.29 (-0.15%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • DOW

    29,590.41
    -486.27 (-1.62%)
     
  • CRUDE OIL

    79.43
    -4.06 (-4.86%)
     
  • GOLD FUTURES

    1,651.70
    -29.40 (-1.75%)
     
  • NIKKEI 225

    27,153.83
    -159.30 (-0.58%)
     
  • HANG SENG

    17,933.27
    -214.68 (-1.18%)
     
  • DAX

    12,284.19
    -247.44 (-1.97%)
     
  • CAC 40

    5,783.41
    -135.09 (-2.28%)
     

Unaudited NAV for August 2022

·1-min read

Arix Bioscience PLC (ARIX)
Unaudited NAV for August 2022
15-Sep-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

 

Arix Bioscience plc

 

Unaudited NAV for August 2022

 

LONDON, 15 September 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 31 August 2022 as follows:

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

31 August 22

(unaudited)

£41.4m

£56.7m

£129.9m

£2.0m

£230.0m

£1.78

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:

GB00BD045071

Category Code:

MSCM

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

188161

EQS News ID:

1442547


 

End of Announcement

EQS News Service

show this
show this